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Background:  It was reported that N,N,N'N'-tetrakis- [2-pyridylmethyl]-ethylenediamine (TPEN), a transition metal 
chelator, confers cardioprotection against myocardial ischemic injury.  In this study, we investigated the effect of 
TPEN targeting reperfusion period in isolated rat hearts. 
Methods:  Langendorff perfused rat hearts were subjected to 30 min of regional ischemia and 2 h of reperfusion. 
Hearts were randomly assigned to either control (n = 9) or 10 μM of TPEN (n = 8) groups.  TPEN was perfused for a 
period of 5 min before and 30 min after reperfusion. 
Results:  The ratio of infarct area/ischemic area (AN/AR) was significantly reduced in TPEN treated hearts (6.9 ± 1.7%, 
P < 0.001) compared to control hearts (29.5 ± 3.2%).  Recovery of left ventricular developed pressure (LVDP), rate-
pressure product (RPP), +dP/dtmax, and -dP/dtmin in the control group after reperfusion were 53.8 ± 6.2%, 51.0 ± 6.3%, 
51.9 ± 5.7%, and 51.4 ± 5.7%, respectively, of the baseline levels.  In the TPEN group, LVDP, RPP, +dP/dtmax, and 
-dP/dtmin returned to 58.5 ± 4.6%, 54.8 ± 6.4%, 61.7 ± 4.9%, and 53.4 ± 3.9%, respectively, of the baseline levels. There 
were no significant differences in the cardiodynamic variables between the two groups (P > 0.05). 
Conclusions:  Pharmacological postconditioning with TPEN reduces myocardial infarction however, TPEN does not 
modify post-ischemic systolic dysfunction in isolated rat hearts.  (Korean J Anesthesiol 2010; 58: 290-295)
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Introduction 
    Because pretreatment with ischemic or pharmacological 
preconditioning is seldom possible in patients with 
ongoing acute myocardial infarction, strategies that directly 
target reperfusion could be more reliable. In this regard, 
ischemic postconditioning (I-Post) and pharmacological 
postconditioning (P-Post) have generated considerable interest 
recently. I-Post, which entails brief repetitive mechanical 
interruptions during early reperfusion, has reduced myocardial 
infarction in dogs [1], rodents [2], and even humans [3]. The 
infarct limitation effect by I-Post is as effective as that of 
ischemic preconditioning (I-Pre) [1]. In addition, P-Post with 
various adjuvants, such as opioid, bradykinin, insulin, and 
urocontin, has also been shown to provide cardioprotection 
[4-7].  
    N,N,N'N'-Tetrakis- [2-pyridylmethyl]-ethylenediamine 
(TPEN) is a high-affinity chelator of transition metals, such 
as Zn
2+. TPEN also binds Ca
2+ with a low affinity, and its fast 
diffusion across membranes renders it an intracellular Ca
2+ 
buffer [8]. It has been proposed that ischemic pretreatment 
with TPEN confers cardioprotection in rat cardiomyocytes [9] 
and hearts [10], and TPEN treatment before and during hypoxia 
induces activation of a sarcolemmal Na
+/Ca
2+ exchanger and 
increases Ca
2+ extrusion from the cytoplasm of cardiomyocytes, 
preventing cytosolic Ca
2+ overload in cultured cardiomyocytes 
[9]. Furthermore, TPEN administered prior to ischemia has 
exerted beneficial effects on post-ischemic cardiac function; 
it has also reduced ventricular fibrillation (VF) incidence as 
well as the incidence and duration of ventricular tachycardia 
in in vivo rat hearts [10]. However, the TPEN induced 
myocardial infarct limitation effect, which is considered a more 
reliable endpoint than functional recovery [11], has not been 
characterized.
    Interestingly, some drugs protect the myocardium against 
ischemic injury but not against reperfusion injury and vice versa 
[12-14]. In this regard, it should be determined whether TPEN 
also provides cardioprotection when administered during the 
reperfusion period, which is a more suitable management time 
in clinical settings. Thus far, however, there is scant information 
about targeting TPEN during the reperfusion phase and the 
subsequent effects it would have on infarct limitation and 
cardiac function recovery. 
    Therefore, in this study, we examined whether P-Post with 
TPEN at the concentrations that are cardioprotective against 
ischemia could reduce myocardial infarct size and induce 
cardiodynamic functional recovery in an isolated rat heart 
model. 
Materials and Methods
Langendorff isolated heart perfusion preparation
    Male Sprague-Dawley rats (280-330 gm) were obtained 
from Korea Taconic Company. Rats were anesthetized with 
100 mg/kg of pentobarbital sodium (Entobar
Ⓡ, Hanlim 
Pharmacy, Korea), and 300 IU of heparin was administered 
intraperitoneally. Coronary perfusion by the Langendorff 
system with modified Krebs-Henseleit (KH) solution, 
containing 118.5 NaCl, 4.7 KCl, 1.2 MgSO4, 1.8 CaCl2, 24.8 
NaHCO3, 1.2 KH2PO4, and 10 glucose (in mM), was performed 
as previously described in detail in our previous reports [15,16].
Making of ischemia and reperfusion 
    All hearts were allowed to stabilize for at least 20 min before 
ischemia induction. Hearts were subjected to 30 min of regional 
ischemia and 120 min of reperfusion. To induce regional 
ischemia, a snare was made at the level of the proximal length of 
the left coronary artery (LCA). Regional ischemia was induced 
by pulling the snare and confirmed by regional cyanosis and 
a substantial decrease in left ventricular developed pressure 
(LVDP). Reperfusion was started by releasing the snare. Hearts 
experiencing VF after reperfusion usually revert spontaneously 
to sinus rhythm. VF lasting more than 30 s was treated with 
finger flick cardioversion until a perfusing rhythm was obtained. 
No pharmacological agents were used for defibrillation.
Assessment of cardiac function 
    In isolated hearts, a KH buffer-filled latex balloon was 
inserted into the left ventricle (LV) and was adjusted to 5-10 
mmHg of the left ventricular end-diastolic pressure (LVEDP) 
at the beginning of the experiment. Cardiodynamic variables, 
including heart rate (HR), left ventricular systolic pressure 
(LVSP), and LVEDP, were recorded with the MP150 system 
(BIOPAC Systems Inc., USA). LVDP and rate-pressure product 
(RPP) were calculated as follows: LVDP = LVSP - LVEDP and 
RPP = LVDP × HR. Maximum (+dP/dtmax) and minimum (-dP/
dtmin) of the first derivative of LV pressure were analyzed using 
the Acqknowledge software (version 3.9.0.). Coronary flow (CF) 
was measured by perfusate dripping from the right heart into a 
graduated cylinder. 
Experimental protocol
    Isolated rat hearts were assigned randomly to one of the 
following two groups: 1) Control; no other intervention either 
before or after LCA occlusion (n = 9), and 2) TPEN; 10 μM 292 www.ekja.org
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of TPEN (n = 8). TPEN (Sigma-Aldrich Chemical, USA) was 
infused for a period of 5 min before and 30 min after reperfusion 
(Fig. 1). TPEN was dissolved with dimethyl sulfoxide and stored 
at -20
oC. TPEN was diluted with KH solution to the required 
final concentrations, as described above, on the day of each 
experiment. The concentration of TPEN used in this study was 
based on a previous study for isolated working rat hearts [10]. 
Exclusion criteria
    We decided prospectively that any hearts with a HR < 250 
beats/min, those failing to develop LVSP > 80 mmHg when 
the LVEDP was kept at 5-10 mmHg, or CF > 18 ml/min or < 8 
ml/min at the end of stabilization would be excluded from the 
study. 
Determination of ischemic and infarct zone
    At the end of each experiment (2 h reperfusion), ischemic 
(area at risk, AR) and infarcted (area of necrosis, AN) regions 
were measured with fluorescent polymer microspheres (Duke 
Scientific Corp., USA) and 2,3,5-triphenyltetrazolium chloride 
(TTC, Sigma-Aldrich Chemical, USA) staining as described 
previously [15]. The AR and AN regions were quantified with the 
ImageTool program (UTHSCSA Image Tool, version 3.0). Infarct 
size was expressed as a percentage of the risk zone (AN/AR). 
All measurements were performed in a blinded fashion. Body 
weight (mean 302.2 ± 4.4 gm) and heart weight (mean 1.54 ± 0.04 
gm) were equivalent between the two groups.
Statistical analysis
    Data are expressed as means ± SEM. Statistical significance was 
determined using a t-test (SPSS for Windows, version 12.0). A P 
value less than 0.05 was considered to be statistically significant.
Results
    All hearts for this experiment were perfused within 30 s after 
excision. A total of 19 rat hearts were used for the infarct size 
measurement study. Two hearts were excluded for the following 
reasons: HR < 250 beats/min (1) and CF > 18 ml/min (1) after 
the stabilization period. Therefore, we report the data for 17 
hearts that successfully completed the infarct experiment study. 
The incidence of VF during the first 30 min after reperfusion 
was 67% (6/9) in the control group and 62% (5/8) in the TPEN 
group, respectively. Statistical analysis was not performed for 
the occurrence of VF, because of the small sample size. Hearts 
experiencing VF after reperfusion usually reverted to sinus 
rhythm spontaneously or by finger flick cardioversion. 
Infarct size
    Fig. 2 represents the AN/AR ratio after 2 h of reperfusion by 
TTC stain. AN in control hearts was 29.5 ± 3.2% of the AR, which 
is in agreement with our recently reported infarct measurement 
study [15,16]. AN/AR of the TPEN group was significantly 
reduced (6.9 ± 1.7%) compared to control hearts (P < 0.001). 
Functional recovery 
    Baseline CF and HR after stabilization are shown in Table 1 and 
were comparable between the groups, averaging 11.8 ± 0.5 ml/min 
and 273.6 ± 3.1 beats/min, respectively. CF abruptly decreased 
after ischemia and diminished continuously during reperfusion 
without achieving statistically significant differences between 
Fig. 1. Experimental protocol of isolated heart perfusion. Rats were 
subject to 30 min of regional ischemia followed by 2 h of reperfusion. 
TPEN (N,N,N'N'-Tetrakis-[2-pyridylmethyl]-ethylenediamine) was 
perfused for a period of 35 min, from 5 min before reperfusion to 30 
min after reperfusion (dashed box).
Fig. 2. Area of necrosis (AN) as percentage of area at risk (AR) as 
evaluated by triphenyltetrazolium chloride (TTC) staining following 
30 min of regional ischemia and 2 h of reperfusion in an isolated 
rat heart model. AN/AR significantly decreased in TPEN-treated 
hearts compared to untreated control hearts. Open circles indicate 
the infarct sizes from individual hearts. Filled circles in each group 
indicate the group mean infarct size; mean ± SEM. TPEN: N,N,N'N'-
tetrakis-[2-pyridylmethyl]-ethylenediamine. *P < 0.001 vs. control.293 www.ekja.org
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the two groups. There was no statistically significant difference 
in HR throughout the experiment between the groups (data not 
shown).  
    Baseline values of cardiodynamic parameters after 
stabilization are also shown in Table 1. There was no significant 
difference in baseline cardiodynamic parameters between 
the two groups (P > 0.05). Fig. 3 shows recovery of LVDP, RPP, 
+dP/dtmax, and -dP/dtmin after 2 h of reperfusion compared 
to baseline levels. There were no significant differences in 
cardiodynamic variables between the two groups (P > 0.05). 
Discussion 
    TPEN is a drug that was proposed to protective against my-
ocardial ischemic injury and reduce post-ischemic cardiac 
damage [17]. Until now, most of the studies on TPEN's 
cardioprotective effect were performed on ischemic 
pretreatment, and the effect of P-Post with TPEN remained. The 
present study has shown for the first time that targeting the use 
of TPEN, a metal chelator, during the reperfusion phase limits 
myocardial infarction. In addition, the study showed that there 
were no differences in cardiodynamic parameters, such as 
LVDP, RPP, +dP/dtmax, and -dP/dtmin, between TPEN-treated 
and non-treated hearts. Our data showed that P-Post with 
TPEN reduces myocardial infarct size but does not improve the 
functional recovery after reperfusion in isolated rat hearts. 
    Although tissue salvage by an anti-infarct intervention leads 
to improvement of cardiac function, infarct size limitation 
does not always produce mechanical functional recovery of 
hearts after myocardial ischemic/reperfusion (I/R) injury. For 
example, a potent opioid such as fentanyl, or angiotensin II 
reduces infarct size but does not protect against myocardial 
dysfunction in isolated rat hearts [18,19]. In addition, there are 
also several lines of evidence that I-Pre and I-Post also limit 
infarct size but do not reduce myocardial dysfunction [20,21]. 
The adenosine receptor agonist AMP579 or nitric oxide donors, 
on the other hand, alleviate both myocardial infarct size and 
dysfunction [22,23]. The discrepancy between infarct limitation 
and cardiac function recovery may be explained by continued 
stunning, or the possibility that the salvaged tissue is not yet 
normal [11]. Myocardial stunning is prolonged myocardial 
dysfunction with the histological absence of necrosis after I/R 
injury. It is proposed that stunning occurs in reversibly injured 
cells or via nonlethal injury to the epicardial border zones 
surrounding infarcted myocardium [24]. Although cellular 
ATP levels or free radicals have been proposed to be important 
mediators for stunning [25], the exact mechanism responsible 
for stunning remains unclear. Another possible mechanism 
for myocardial stunning is an increase in the concentration 
of intracellular Ca
2+. The increase in the Ca
2+ concentrations 
in myocardial cells is likely explains the depressed ability of 
I/R hearts to generate contractile force [26]. In our present 
study, targeting TPEN during the reperfusion period reduced 
myocardial infarction but did not attenuate post-ischemic 
systolic dysfunction, even though TPEN has a Ca
2+ buffer 
action. We do not know the exact reason for this, but the Ca
2+ 
buffer action of the TPEN concentration (10 μM) used during 
reperfusion might not be enough to attenuate myocardial 
systolic dysfunction. 
    It has been previously demonstrated that TPEN reduces 
basal cardiac nitric oxide (NO) content and prevents the 
Table 1.  Baseline Coronary Flow and Cardiodynamic Data after Stabilization
 Group
Coronary flow
(ml/min)
Heart rate 
(beats/min)
LVDP 
(mmHg)
RPP 
(mmHg·beats/min·10
3)
+dP/dtmax
 (mmHg/s/10
3)
-dP/dtmin 
(mmHg/s/10
3)
 Control
 TPEN 
12.6 ± 0.6
11.0 ± 0.5
270.9 ± 5.0
276.6 ± 3.4
130.3 ± 4.3
139.9 ± 6.9
35.3 ± 1.4
38.7 ± 2.0
3.0 ± 0.3
2.6 ± 0.2
-2.7 ± 0.2
-2.7 ± 0.2
Values are means ± SEM. TPEN: N,N,N'N'-tetrakis-[2-pyridylmethyl]-ethylenediamine, LVDP: left ventricular developed pressure, RPP: rate-
pressure product, +dP/dtmax: velocity of contraction, -dP/dtmin: velocity of relaxation. There are no significant differences between groups 
(t-test).
Fig. 3. Percentage changes in left ventricular developed pressure 
(LVDP), rate-pressure product (RPP), velocity of contraction 
(+dP/dtmax), and velocity of relaxation (-dP/dtmin) after 2 h of 
reperfusion compared to baseline levels in isolated rat hearts. 
There were no significant differences in cardiodynamic variables 
between the two groups. TPEN: N,N,N'N'-tetrakis-[2-pyridylmethyl]-
ethylenediamine. Values are means ± SEM. 294 www.ekja.org
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accumulation of NO during myocardial I/R [9]. In addition it 
has been proposed that lowering sarcolemmal Ca
2+ content 
may be a mechanism underlying the recently reported 
cardioprotective and anti-arrhythmic features of TPEN [9,10]. A 
chelator is a substance consisting of molecules that bind tightly 
to metal atoms, thus forcing the metal atoms to go wherever 
the chelator goes. Though TPEN has been used mainly as a 
heavy metal (e.g. Zn
2+) chelator, it has a low affinity for Ca
2+ 
as well and its fast diffusion across membranes make TPEN 
a membrane permeable buffer for Ca
2+ within intracellular 
stores [8]. Recently, Shmist et al. [9] demonstrated that 
TPEN improves myocardial protection against ischemia by 
modulation of intracellular Ca
2+ homeostasis. Jung et al. [27] 
also demonstrated that myocardial protection by TPEN has 
been related to its modulation of Ca
2+ homeostasis through 
the activation of the Na
+/Ca
2+ exchanger leading to increased 
extrusion of Ca
2+ from the cytoplasm in ventricular myocytes. 
However, the exact mechanism of the cardioprotective effect 
achieved by targeting the administration of TPEN during the 
reperfusion period has not yet been well established and should 
be determined in the future. 
    Interestingly, some drugs protect the myocardium when used 
during the ischemic phase but not in the reperfusion phase and 
vice versa [12-14]. In this study, administrating TPEN during the 
reperfusion phase effectively reduced myocardial infarction. 
Taken together with other previous reports on the effect of PEN 
treatments targeting ischemia [8,9], one can propose that TPEN 
has anti-ischemic and reperfusion injury protective effects. 
    It is also interesting that TPEN acts as a membrane per-
meable Zn
2+ chelator, i.e., TPEN reduces intracellular Zn
2+ 
concentrations. Zn
2+ is essential in maintaining the structure 
and function of cell membranes, and it plays an important 
role in the maintenance of the activity of various enzymes [28]. 
Recently, several lines of evidence documented that exogenous 
Zn
2+ may lead to cardioprotection against reperfusion 
injury [29,30]. In our study, TPEN administration during the 
reperfusion phase significantly reduced myocardial infarction, 
even though TPEN reduces intracellular Zn
2+ concentrations. 
The reason for this is unclear, but we can propose that the Ca
2+ 
buffering effect of TPEN may be a more important mechanism 
for the limitation of infarction than the ability to lower the Zn
2+ 
concentration. 
    We conclude that P-Post with a 10 μM concentration of 
TPEN, which is proposed to have a cardioprotective effect 
during ischemia, limits myocardial infarction but does not 
attenuate myocardial dysfunction in isolated rat hearts. Further 
studies are needed to determine the exact mechanism for this 
discrepancy. 
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